Vivanza Biosciences Share Price

Vivanza Biosciences Investment Rating

• Master Rating:

• Vivanza Biosciences has an operating revenue of Rs. 12.52 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 3% needs improvement, ROE of 9% is fair but needs improvement. The company has a debt to equity of 74%, which is bit higher. It is currently FORMING a base in its weekly chart and is trading around 7% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 10 which is a POOR score indicating inconsistency in earnings, a RS Rating of 69 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 96 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.